Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Retained Earnings (2021 - 2026)

Centessa Pharmaceuticals has reported Retained Earnings over the past 5 years, most recently at -$1.2 billion for Q4 2025.

  • Quarterly Retained Earnings fell 19.98% to -$1.2 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$1.2 billion through Dec 2025, down 19.98% year-over-year, with the annual reading at -$1.2 billion for FY2025, 19.98% down from the prior year.
  • Retained Earnings was -$1.2 billion for Q4 2025 at Centessa Pharmaceuticals, down from $2.6 million in the prior quarter.
  • Over five years, Retained Earnings peaked at $2.6 million in Q3 2025 and troughed at -$1.2 billion in Q4 2025.
  • The 5-year median for Retained Earnings is -$385.7 million (2021), against an average of -$434.7 million.
  • Year-over-year, Retained Earnings plummeted 131951.92% in 2024 and then surged 100.3% in 2025.
  • A 5-year view of Retained Earnings shows it stood at -$385.7 million in 2021, then skyrocketed by 99.61% to -$1.5 million in 2022, then plummeted by 50196.93% to -$752.9 million in 2023, then crashed by 31.31% to -$988.7 million in 2024, then fell by 19.98% to -$1.2 billion in 2025.
  • Per Business Quant, the three most recent readings for CNTA's Retained Earnings are -$1.2 billion (Q4 2025), $2.6 million (Q3 2025), and $1.6 million (Q2 2025).